| Sagliker syndrome in a patient with secondary hyperparathyroidism and chronic renal insufficiency: a case report S Shakeri, SZ Moghadam, R Sadeghi, N Ayati Asia Oceania Journal of Nuclear Medicine and Biology 6 (2), 167, 2018 | 14 | 2018 |
| Favorable response after only one cycle of peptide receptor radionuclide therapy with 177Lu-DOTATATE in a patient with metastatic Merkel cell carcinoma SZ Moghadam, G Divband, S Shakeri, K Aryana Clinical Nuclear Medicine 44 (8), 650-652, 2019 | 12 | 2019 |
| Peptide receptor radionuclide therapy in merkel cell carcinoma: a comprehensive review E Askari, SZ Moghadam, D Wild, E Delpassand, S Baldari, B Nilica, ... Journal of Nuclear Medicine Technology 51 (1), 22-25, 2023 | 10 | 2023 |
| 68Ga-FAPI-46 PET/CT in a metastatic castration-resistant prostate cancer patient with low PSMA expression K Aryana, R Manafi-Farid, H Amini, G Divband, SZ Moghadam Clinical Nuclear Medicine 47 (11), 972-973, 2022 | 10 | 2022 |
| Evaluation of 95 cases with Mediastinal tumors R Bagheri, R Afghani, S Ziaollah Haghi, SH Fattahi Masoum, ... Journal of Cardio-Thoracic Medicine 3 (1), 249-253, 2015 | 9 | 2015 |
| Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with 177Lu-PSMA-617: a single center study SZ Moghadam, E Askari, G Divband, S Shakeri, K Aryana Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 41 …, 2022 | 6 | 2022 |
| 177Lu-Prostate-Specific Membrane Antigen Super Scan and Good Response Even After 1 Cycle of Radioligand Therapy. K Aryana, S Zarehparvar Moghadam, R Salek, G Divband Clinical nuclear medicine 43 (4), 273-275, 2018 | 3 | 2018 |
| 99mTc-PSMA Left Behind: a Call for Collaboration SZ Moghadam, E Askari, K Aryana Nuclear Medicine and Molecular Imaging 56 (4), 218-219, 2022 | 2 | 2022 |
| Amino acid extravasation: a rare red flag to keep in mind during peptide receptor radioligand therapy (PRRT) with [177Lu] Lu-DOTATATE G Divband, SH Alavi, Z Adinehpour, F Kalantari, ... Nucl. Med. Rev. Cent. East. Eur 25, 136-137, 2022 | 2 | 2022 |
| [68Ga] Ga-PSMA-11 PET/CT for staging and patient management of high-risk prostate cancer: A single-center experience from Iran S Shakeri, E Askari, S Zarehparvar, F Farahmandfar, N Norouzbeigi, ... Iranian Journal of Nuclear Medicine 30 (1), 33-39, 2022 | 2 | 2022 |
| Fact Checking on 177Lu Prostate-Specific Membrane Antigen Nephrotoxicity E Askari, SZ Moghadam, K Aryana American Journal of Roentgenology 215 (1), W2-W2, 2020 | 2 | 2020 |
| Benign High-Flow Priapism With a Diffuse and Intense 18F-FDG Uptake on 18F-FDG PET/CT Scanning Z Nasiri, S Zarehparvar Moghadam, Z Kiamanesh, F Emami, R Sadeghi Clinical Nuclear Medicine 44 (7), 442-444, 2019 | 2 | 2019 |
| Medical Event: Accidental Oral Administration of: 177: Lu-PSMA to a Patient With Hyperthyroidism SZ Moghadam, A Aghaee, M Esmatinia, N Nateghi, K Aryana Clinical Nuclear Medicine 45 (6), 439-441, 2020 | 1 | 2020 |
| Complete Resolution of Locally Advanced Prostate Cancer After Molecular Endoradiotherapy With 177Lu-PSMA M Beheshti, R Vali, SZ Moghadam, HR Amini, M Hakiminejad, ... Clinical Nuclear Medicine, 10.1097, 2024 | | 2024 |
| Combination of peptide receptor radionuclide therapy and immune checkpoint inhibitor in metastatic Merkel cell carcinoma SZ Moghadam, R Manafi-Farid, P Nghiem, L Gunnell, E Askari | | 2024 |
| Combination of peptide receptor radionuclide therapy and immune checkpoint inhibitor in metastatic Merkel cell carcinoma S Zarehparvar Moghadam, R Manafi-Farid, P Nghiem, L Gunnell, E Askari Iranian Journal of Nuclear Medicine 32 (1), 99-101, 2024 | | 2024 |
| Long-term Durable Response after Treatment with 177Lu-PSMA Therapy in Combination with Enzalutamide SZ Moghadam, E Askari, N Ayati, G Divband, K Aryana Journal of Clinical and Medical Images Case Reports 2 (6), 2022 | | 2022 |
| Factores pronósticos de eficacia y seguridad que afectan a la supervivencia global de los pacientes con cáncer de próstata metastásico sometidos a tratamiento con [177Lu] Lu … SZ Moghadam, E Askari, G Divband, S Shakeri, K Aryana Revista Española de Medicina Nuclear e Imagen Molecular 41 (4), 239-246, 2022 | | 2022 |
| After two consecutive rises in PSA level following treatment with 177Lu-PSMA-617 in mCRPC patients, is there any chance for PSA response with an additional cycle? A … HM Kosari, E Askari, SZ Moghadam, K Aryana Journal of Nuclear Medicine 63 (supplement 2), 3062-3062, 2022 | | 2022 |
| Whole-Body 177Lu–Prostate-Specific Membrane Antigen Scan Pattern With Excess Free 177Lu-Chloride in a Metastatic Castration-Resistant Prostate Cancer Patient E Askari, SZ Moghadam, G Divband, K Aryana Clinical Nuclear Medicine 45 (10), 805-807, 2020 | | 2020 |
Kamran AryanaAssistant professor of nuclear medicineVerified email at mums.ac.ir
